Lipella Pharmaceuticals

LIPOPhase 2

Lipella Pharmaceuticals leverages its proprietary liposomal delivery platform to develop targeted therapies for mucosal diseases where traditional treatments struggle. The company has a diversified pipeline with LP-10 in Phase 2 trials for oral lichen planus, hemorrhagic cystitis, and oral graft-versus-host disease, and LP-50 in preclinical development for bladder cancer. Their strategy focuses on repurposing proven drugs through the 505(b)(2) regulatory pathway to accelerate development and reduce risk.

Market Cap

$693K

Focus

DiagnosticsSmall Molecules

LIPO · Stock Price

USD 0.1545.85 (-99.67%)

Historical price data

AI Company Overview

Technology Platform

Proprietary liposomal drug delivery platform engineered for targeted treatment of mucosal surfaces in the bladder, oral cavity, urethra, esophagus, and colon, enabling localized therapy with reduced systemic side effects.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
LP-10	Hemorrhagic Cystitis	Phase 2
LP-10 (Liposomal Tacrolimus)	Oral Lichen Planus	Phase 2
LP-08 80mg + Normal saline + LP-08 20mg	Interstitial Cystitis	Phase 2
Ferumoxytol + Gadobutrol	IC - Interstitial Cystitis	Phase 1

Opportunities

Multiple orphan drug designations provide regulatory advantages and potential market exclusivity.

The platform's versatility across mucosal surfaces enables expansion into additional indications beyond current pipeline.

The 505(b)(2) pathway offers faster development timelines and reduced regulatory risk compared to novel chemical entities.

Risk Factors

Clinical trial failures in Phase 2 programs could significantly impact valuation and future financing.

Competition from larger pharmaceutical companies with similar delivery technologies poses market entry challenges.

Dependence on the 505(b)(2) regulatory pathway carries inherent risks if FDA requirements evolve or become more stringent.

Competitive Landscape

Faces competition from both traditional systemic therapies and emerging localized delivery technologies. Differentiation lies in platform versatility across multiple mucosal surfaces and the 505(b)(2) development strategy. Key competitors include other drug delivery specialists and companies developing targeted biologics for inflammatory conditions.